Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents
Table 1
Demographic characteristics and clinical history by receipt of HER2-targeted agents.
No treatment
No HER2-targeted agents
HER2-targeted agents
All patients—
= 2,590
= 12,840
= 2,629
Age, mean (SD)
62.3 (13.6)
60.1 (12.7)
55.6 (11.2)a
Urban
82.8%
84.4%
83.6%
Payer
a
Commercial
64.0%
68.4%
83.5%
Medicare
36.0%
31.6%
16.6%
Insurance plan typed
a
Comprehensive
16.6%
15.5%
9.6%
EPO or PPO
52.6%
51.3%
57.1%
POS
6.6%
7.7%
9.1%
HMO
16.1%
16.8%
15.3%
CDHP or HDHP
3.2%
3.6%
4.0%
Unknown
4.8%
5.2%
5.1%
Earlier stage breast cancer diagnosis
66.7%
71.2%
72.7%a
Surgery for breast cancere
15.6%
22.0%
26.0%a
Adjuvant/neoadjuvant treatmentf
n/a
66.8%
77.8%a
Radiation therapye
10.7%
15.4%
17.9%a
Any antineoplastic treatmente
n/a
75.4%
79.4%a
Hormone therapy
n/a
55.4%
33.9%a
Chemotherapy
n/a
27.8%
44.5%a
Non-HER2 biologic/HER2-targeted agent
n/a
4.9%
63.2%a
HER2-targeted agents
n/a
n/a
62.4%
Charlson Comorbidity Index (CCI), mean (SD)
3.41 (2.37)
3.71 (2.63)
3.87 (2.75)a
NCCI, mean (SD)
1.66 (1.05)
1.54 (0.97)
1.45 (0.89)a
Comorbidities
Anemia
11.9%
12.5%
14.0%c
Anxiety/depression
7.4%
7.5%
8.7%
Cardiac arrhythmia
10.4%
9.5%
6.5%a
Cerebrovascular disease
6.0%
4.3%
2.3%a
Congestive heart failure
4.3%
3.2%
3.1%c
Coronary artery disease
7.7%
6.9%
5.2%b
Chronic obstructive pulmonary disorder
6.0%
5.3%
3.2%a
Diabetes
14.8%
14.6%
11.4%a
Hypertension
38.9%
37.3%
29.2%a
Number of metastasis sites at index, mean (SD)
1.48 (0.84)
1.54 (0.82)
1.62 (0.88)a
Site of metastasis at index
Liver
12.4%
12.1%
17.2%a
Lung
14.9%
12.1%
13.5%b
Bone
29.5%
42.2%
36.2%a
Brain
11.9%
8.1%
14.0%a
= number of patients meeting study selection criteria. value compared with no treatment and no HER2-targeted agents <0.0001. value compared with no treatment and no HER2-targeted agents <0.01. value compared with no treatment and no HER2-targeted agents <0.05.
dEPO: exclusive provider organizations, PPO: preferred provider organization plans, POS: point-of-service, HMO: health maintenance organization, CDHP: consumer-driven health plan, and HDHP: high deductible health plan.
eThe denominator for the percentages is the number of patients with a diagnosis of an earlier stage breast cancer. fPercent of patients with surgery in the preindex period.
